News

CirQuest Labs Hiring Research Associate

We are currently looking for experienced Research Associate candidates, please contact us if you are interested. For more information on this position’s qualifications and responsibilities please click here.

Find CirQuest at ISTH 2017

Our Founder and CEO, Dr. Lisa K. Jennings, will be attending ISTH 2017 from July 8th – 13th in Berlin. Please click here to schedule a meeting with her or email us directly.

CirQuest Labs is Expanding

We are excited to announce our upcoming move to a larger space. As leaders in innovative life science services we look forward to expanding services to our clients and providing guidance to local startup companies. http://www.commercialappeal.com/story/money/business/development/2017/05/22/cirquest-labs-moving-larger-space/337202001/

 

Paid Clinical Trial Research Study – Now Enrolling – Memphis, TN

Research Volunteers Needed

CirQuest Labs is currently seeking Volunteers to donate blood for a clinical study of vascular disease.

If you are between the ages of 18 and 65, you may be eligible to participate. This is a one time blood collection study only. No drug treatment will be provided; however, you will be contacted once by Phone 5 days following the blood draw.

Qualified participants will be paid $50 at the completion of the study.

CirQuest Labs is conveniently located in mid-town Memphis in the Medical Center district. For more information, call: 901-866-1700, Ext. 2

Recruiting Flyer 2014-06-11

CirQuest Labs Expands Molecular Oncology and Companion Testing Services CirQuest Oncology Division

CirQuest Labs (Memphis, TN) announces a substantial advance in the specialized laboratory services area. Expanding upon its established skills in cardiovascular disease and immunohematology, CirQuest now provides the latest techniques in oncology research and development and extensive companion testing in the clinical oncology field.
Companion biomarker testing emphasizes new and developing technology platforms designed to aid in the advancement of drugs for patient care. According to Lisa Jennings, PhD, Founder and CEO of CirQuest Labs, “the use of companion testing has the potential to yield safer and more efficacious drugs, while reducing clinical trial and development costs. This technology enables substantial headway to be made in “Go/No Go” decision making.”

CirQuest Oncology Panel:

– Multiple Array Technologies
– Viral Load Assessment
– qRT-PCR
– Genome-wide Microarrays
– Next Generation Sequencing
– Epigenetic Study Support (methylated DNA and microRNAs arrays)
– Genetic Variation and Mutation Assays
– Flow Cytometry (antigen detection, absolute cell counts, cell signaling, DNA analysis, immunophenotyping)
– Soluble Biomarkers (cytokines, chemokine, MMPs, MP)
– Cancer-Platelet Interactions (static and microfluidic assays)
– Cell Migration and Invasion Assays
– 3D Tissue Culture Expertise
– Immunoprecipitations, SDS/PAGE, Western blot
– Complete Histopathology Analysis (tissue biomarkers)

CirQuest Oncology provides significant enhancements to the broad services portfolio of scientific and laboratory expertise that we bring to research and development on behalf of our clients,” said Jennings.

CirQuest Labs, founded in 2008, continues to expand services to provide precision testing in medical specialties and to meet the increasing need for companion diagnostics, specialized testing, and clinical trial laboratory support services. CirQuest Labs is a leading global provider of specialized life science services. Core experience and expertise are in the vascular and tumor cell biology areas, including hemostasis, thrombosis, and immunohematology. CirQuest offers a broad spectrum of cellular and soluble biomarker analyses in many health-related disciplines. Other divisions within the company include global clinical trial support services and biologistics, including sample storage.

For more information about this topic, or to schedule an interview with Dr. Jennings, please contact:

Colleen S. Hoke
Business Officer
colleenhoke@cirquestlabs.com
Cell: (425) 260-1131

Taking Aspirin or Plavix??

CQRP-1 WIRB#20111200 Revised Flyer 11.11.13

Academic Alliance – Memphis Chapter

Academic Alliance

Lisa Jennings, PhD, Founder/CEO of CirQuest Labs, addresses the first meeting of the Academic Alliance, Memphis Chapter. The meeting was hosted by Life Science Tennessee and supported by St. Jude Children’s Research Hospital, University of Memphis, University of Tennessee Health Science Center and Memphis Bioworks. The Academic Alliance is a forum for graduate students, post-docs and academics from Memphis’ higher education institutions to learn about and engage with the life sciences industry in Tennessee.

CirQuest Labs Expanding Predictive Laboratory Analytic Capabilities

Press Release

MEMPHIS T.N., (October 2, 2013) – CirQuest Labs is expanding predictive laboratory analytic capabilities to meet the growing needs of clients seeking to determine how persons’ genetic differences may affect their response to drug therapy. The breakthrough analytical technology and companion bioinformatics makes it possible to determine the effects of genetic variation on drug efficiency, drug metabolism and drug toxicity early in the drug development process.

The technology, in partnership with Varigenix, employs large panels of cultured hepatocytes (liver cells) that have genetic variation characteristics that are comparable to large human populations. Varigenix, guided by President and CEO, Robert E. Scott, MD, is a systems genetics-based company focused on the importance of genetic variation in drug development and drug testing. The use of this new approach to pharmacogenomic and toxicogenomic studies is also designed to help make drug development more efficient and more predictive of clinical outcomes.

“Biotech and pharmaceutical companies are shifting their strategies to reduce attrition and increase the potential for drug efficacy by incorporating genomics into their drug discovery and development practices. Potential uses of this technology include the evaluation of genetic variation in drug development and drug metabolism as well as a wide range of pharmacogenomic and toxicogenomics applications. Utilizing this technology will help determine the drug candidates that may have the greatest potential for clinical success”, said Lisa K. Jennings, PhD, CEO of CirQuest Labs. “Continuing to expand our capabilities to perform additional highly specialized lab services gives clients greater flexibility and efficiency in testing their products”.

CirQuest Labs is a leading global provider of specialized life science services. Core experience and expertise are in the vascular and tumor cell biology areas, including hemostasis, thrombosis, and immunohematology. CirQuest offers a broad spectrum of cellular and soluble biomarker analyses in many health-related disciplines. Other divisions within the company include global clinical trial support services and biologistics, including sample storage.

Contact:
Colleen S. Hoke
Business Officer
20 South Dudley, Suite 900
Memphis, TN 38103
colleenhoke@cirquestlabs.com
Cell: (425) 260-1131
www.cirquestlabs.com

Outsourcing In Clinical Trials – Southeast

Dr. Lisa Jennings will be attending the Outsourcing In Clinical Trials – Southeast conference in Durham, NC May 14 – 16, 2012.

CirQuest at ACC 2012

On March 24, 2012, Dr. Lisa Jennings delivered an oral presentation at the American College of Cardiology’s 2012 Scientific Sessions in Chicago. Dr. Jennings’ talk was entitled, “Pharmacodynamics of Vorapaxar, a Platelet PAR-1 Antagonist, and Its Interaction with P2y12 Receptor Pathway in the TRA•CER Trial“.